Lisata Therapeutics, Inc. (LSTA) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
110 Allen Road
Basking Ridge, NJ 07920
United States of America (the)
Phone
908 842 0100
Website
Sector
Healthcare
Industry
Biotechnology
Employees
26
First IPO Date
March 01, 1999
| Name | Title | Pay | Year Born |
| David J. Mazzo | President, Chief Executive Officer & Director | 735,479 | 1957 |
| William K. Sietsema | Vice President of Global Regulatory Affairs | 350,554 | 1957 |
| James Nisco | Senior Vice President of Finance, Treasurer, CAO & Principal Financial and Accounting Officer | 358,250 | 1972 |
| Kristen K. Buck | Executive Vice President of R&D and Chief Medical Officer | 607,592 | 1974 |
| Gregory S. Berkin | Chief Information & Data Protection Officer | 0 | N/A |
| John D. Menditto | Vice President of Investor Relations & Corporate Communications | 0 | N/A |
| Tariq Imam | Senior Vice President of Business Development & Operations and General Counsel | 0 | 1984 |
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.